BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Angiogen Release: Founder Of Biopharm Startup Publishes Results Of Clinical Cancer Research


10/19/2005 5:11:39 PM

CHICAGO, Oct. 3 /PRNewswire/ -- Angiogen announced today that Dr. Gerald Soff, its Founder and Chief Scientific Officer, is the lead author of an article published in the September 1, 2005 issue of Clinical Cancer Research (Vol. 11, 6218-6225). The article, entitled In vivo Generation of Angiostatin Isoforms by Administration of a Plasminogen Activator and a Free Sulfhydryl Donor: A Phase I Study of an Angiostatic Cocktail of Tissue Plasminogen Activator and Mesna focuses on the results of a clinical study undertaken by Angiogen of its novel anti-angiogenic cancer therapy.

About Angiogen

Angiogen is an Evanston, Illinois based privately held biopharmaceutical discovery company developing novel therapies for treating cancerous solid, vascular tumors. Angiogen's scientific team has world-recognized expertise and experience in angiogenesis inhibition, especially as it relates to the disease of cancer. Angiogen's first therapy, currently in Phase IB/II clinical trials, is based upon combining two classes of FDA approved drugs into one anti-angiogenesis cancer-fighting treatment. Three major biopharmaceutical companies have provided support for Angiogen's clinical research to date. Angiogen continues to explore other diagnostic tests and drug candidates related to its work in angiogenesis field offering hope to the approximately 5 million people worldwide who will die annually from metastatic cancer (555,000 in US). For additional information on Angiogen, please visit our website at: http://www.angiogenesis.com .

About Clinical Cancer Research

Clinical Cancer Research is published twice monthly by the American Association for Cancer Research, Inc. (AACR). The journal publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer. All submissions undergo peer review. For additional information, please telephone: 1-866-423-3965 or visit the web site at: http://clincancerres.aacrjournals.org .

This press release contains forward-looking statements that involve a high degree of technological, regulatory, and competitive risks and uncertainties inherent in early stage biopharmaceutical companies.

Angiogen

CONTACT: Dorene Lynch, +1-847-754-7815, fax, +1-847-864-3291 or email,dlynch@angiogenesis.com , for Angiogen



Read at BioSpace.com

Angiogen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES